Legislation roundup: Pharma monopoly and export, and data interface security risk monitoring
August 16, 2024 | BY
Susan MokSAMR prohibits monopoly agreements that fix or modify pharmaceutical prices. Export pharmaceuticals commissioned for production from a foreign pharmaceutical manufacturer may not be sold and used in the PRC. Guidelines are provided for the methods of monitoring data interface security risks.
Pharmaceuticals
State Administration for Market Regulation, Anti-Monopoly Guidelines for the Pharmaceuticals Sector (Draft for Comments)
国家市场监督管理总局关于药品领域的反垄断指南 (征求意见稿)
Fixing or Modifying Pharmaceutical Prices
Pharmaceutical business operators that are competitors are forbidden from entering